Summary

The global Alfuzosin Hydrochloride Sustained Release Tablets market is projected to grow from US$ 372 million in 2025 to US$ 500 million by 2032, at a CAGR of 4.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Alfuzosin Hydrochloride Extended-Release Tablets are finished prescription oral solid-dose products containing alfuzosin hydrochloride as the sole active ingredient and using a documented sustained, extended, prolonged or modified-release mechanism. The market includes nationally approved 5 mg, 10 mg and other sustained-release strengths; originator brands, branded generics and unbranded generics; multilayer, hydrophilic-matrix, hydrophobic-matrix and mixed-matrix tablets; and blister, bottle and institutional packs sold through retail pharmacies, hospital pharmacies, mail-order pharmacies and public-procurement channels. Immediate-release alfuzosin tablets, active pharmaceutical ingredient, fixed-dose combinations, other alpha blockers, pharmacy dispensing margins, diagnostic services, procedures and clinical-trial supply are excluded. In 2025, the product global weighted average selling price of approximately US$0.39 per tablet, global sales volume of approximately 955 million tablets, and an average gross margin of about 52%. Upstream activities mainly include the production of alfuzosin hydrochloride API, sustained-release matrix materials, binders, fillers, lubricants, coating materials, and pharmaceutical packaging materials. Midstream activities include formulation development, granulation, tableting, coating, dissolution testing, stability testing, bioequivalence studies, regulatory filing, packaging, and batch release. Downstream customers mainly include pharmaceutical wholesalers, retail pharmacies, hospital pharmacies, public procurement agencies, hospitals, and clinics.
Demand is supported by population aging, wider diagnosis of lower urinary tract symptoms and continued use of alpha-blocker therapy for benign prostatic hyperplasia. Once-daily extended-release tablets offer a simpler regimen than immediate-release tablets requiring multiple daily doses.
Unit-volume growth is expected to remain faster than revenue growth. Generic approvals, hospital tenders and public-procurement programs increase access but also reduce the weighted manufacturer selling price.
The 10 mg once-daily formulation is the principal commercial form in the United States and many European markets. Some countries retain 5 mg prolonged-release products administered twice daily, creating differences in prescription volume and tablet consumption.
Modified-release manufacturing presents a higher technical barrier than ordinary immediate-release tablets. Release architecture, food effect, dissolution profiles, stability and bioequivalence must remain consistent during commercial scale-up and post-approval changes.
Administration requirements affect adherence. Current labels generally require the tablet to be swallowed whole, and many products are taken with food or after the same meal each day. Crushing or chewing may alter the intended release profile.
Commercial competition comes from tamsulosin, silodosin and other alpha blockers, as well as five-alpha-reductase inhibitors, tadalafil and fixed-dose treatment strategies. These alternatives limit the share that alfuzosin can obtain from growth in the broader benign prostatic hyperplasia population.
Important commercial and regulatory considerations include postural hypotension, syncope, hepatic impairment, interactions with strong metabolic inhibitors, interval-prolongation caution and disclosure before cataract surgery. These factors influence patient selection, formulary decisions and promotional boundaries.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Alfuzosin Hydrochloride Sustained Release Tablets market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Sanofi
ADVANZ Pharma
Apotex Inc.
Cipla Limited
Sun Pharmaceutical Industries Limited
Unichem Laboratories Limited
Aurobindo Pharma Limited
Wockhardt Limited
Rising Pharma Holdings, Inc.
Zentiva Group, a.s.
Taj Pharmaceuticals Limited
Exelan Pharmaceuticals, Inc.
Lunan Better Pharmaceutical Co., Ltd.
Anxo Pharmaceutical Co., Ltd.
Segment by Type
2.5mg
5mg
10mg
Segment by Prescription Duration
Up to 30 Days
31–90 Days
Above 90 Days
Segment by Brand Positioning
Originator Premium Brand
Regional Branded Generic
Standard Retail Generic
Institutional Tender Generic
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Alfuzosin Hydrochloride Sustained Release Tablets study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Alfuzosin Hydrochloride Sustained Release Tablets: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Alfuzosin Hydrochloride Sustained Release Tablets Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 2.5mg
1.2.3 5mg
1.2.4 10mg
1.3 Market Segmentation by Prescription Duration
1.3.1 Global Alfuzosin Hydrochloride Sustained Release Tablets Market Size by Prescription Duration, 2021 vs 2025 vs 2032
1.3.2 Up to 30 Days
1.3.3 31–90 Days
1.3.4 Above 90 Days
1.4 Market Segmentation by Brand Positioning
1.4.1 Global Alfuzosin Hydrochloride Sustained Release Tablets Market Size by Brand Positioning, 2021 vs 2025 vs 2032
1.4.2 Originator Premium Brand
1.4.3 Regional Branded Generic
1.4.4 Standard Retail Generic
1.4.5 Institutional Tender Generic
1.5 Market Segmentation by Application
1.5.1 Global Alfuzosin Hydrochloride Sustained Release Tablets Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue Estimates and Forecasts (2021-2032)
2.2 Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Estimates and Forecasts (2021-2032)
2.4 Global Alfuzosin Hydrochloride Sustained Release Tablets Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Alfuzosin Hydrochloride Sustained Release Tablets Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Alfuzosin Hydrochloride Sustained Release Tablets Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 2.5mg: Market Share by Key Manufacturers
3.5.2 5mg: Market Share by Key Manufacturers
3.5.3 10mg: Market Share by Key Manufacturers
3.6 Global Alfuzosin Hydrochloride Sustained Release Tablets Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Performance by Type
4.1.1 Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume by Type (2021-2032)
4.1.2 Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Performance by Prescription Duration
4.2.1 Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume by Prescription Duration (2021-2032)
4.2.2 Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Prescription Duration (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Prescription Duration (2021-2032)
4.3 Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Performance by Brand Positioning
4.3.1 Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume by Brand Positioning (2021-2032)
4.3.2 Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Brand Positioning (2021-2032)
4.3.3 Global Average Selling Price (ASP) Trends by Brand Positioning (2021-2032)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Alfuzosin Hydrochloride Sustained Release Tablets Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Alfuzosin Hydrochloride Sustained Release Tablets Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Alfuzosin Hydrochloride Sustained Release Tablets Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Alfuzosin Hydrochloride Sustained Release Tablets Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Alfuzosin Hydrochloride Sustained Release Tablets Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Alfuzosin Hydrochloride Sustained Release Tablets Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Alfuzosin Hydrochloride Sustained Release Tablets Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Alfuzosin Hydrochloride Sustained Release Tablets Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Alfuzosin Hydrochloride Sustained Release Tablets Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Alfuzosin Hydrochloride Sustained Release Tablets Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Alfuzosin Hydrochloride Sustained Release Tablets Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Sanofi
11.1.1 Sanofi Corporation Information
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.1.4 Sanofi Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 Sanofi Alfuzosin Hydrochloride Sustained Release Tablets Sales by Product in 2025
11.1.6 Sanofi Alfuzosin Hydrochloride Sustained Release Tablets Sales by Application in 2025
11.1.7 Sanofi Alfuzosin Hydrochloride Sustained Release Tablets Sales by Geographic Area in 2025
11.1.8 Sanofi Alfuzosin Hydrochloride Sustained Release Tablets SWOT Analysis
11.1.9 Sanofi Recent Developments
11.2 ADVANZ Pharma
11.2.1 ADVANZ Pharma Corporation Information
11.2.2 ADVANZ Pharma Business Overview
11.2.3 ADVANZ Pharma Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.2.4 ADVANZ Pharma Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 ADVANZ Pharma Alfuzosin Hydrochloride Sustained Release Tablets Sales by Product in 2025
11.2.6 ADVANZ Pharma Alfuzosin Hydrochloride Sustained Release Tablets Sales by Application in 2025
11.2.7 ADVANZ Pharma Alfuzosin Hydrochloride Sustained Release Tablets Sales by Geographic Area in 2025
11.2.8 ADVANZ Pharma Alfuzosin Hydrochloride Sustained Release Tablets SWOT Analysis
11.2.9 ADVANZ Pharma Recent Developments
11.3 Apotex Inc.
11.3.1 Apotex Inc. Corporation Information
11.3.2 Apotex Inc. Business Overview
11.3.3 Apotex Inc. Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.3.4 Apotex Inc. Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 Apotex Inc. Alfuzosin Hydrochloride Sustained Release Tablets Sales by Product in 2025
11.3.6 Apotex Inc. Alfuzosin Hydrochloride Sustained Release Tablets Sales by Application in 2025
11.3.7 Apotex Inc. Alfuzosin Hydrochloride Sustained Release Tablets Sales by Geographic Area in 2025
11.3.8 Apotex Inc. Alfuzosin Hydrochloride Sustained Release Tablets SWOT Analysis
11.3.9 Apotex Inc. Recent Developments
11.4 Cipla Limited
11.4.1 Cipla Limited Corporation Information
11.4.2 Cipla Limited Business Overview
11.4.3 Cipla Limited Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.4.4 Cipla Limited Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Cipla Limited Alfuzosin Hydrochloride Sustained Release Tablets Sales by Product in 2025
11.4.6 Cipla Limited Alfuzosin Hydrochloride Sustained Release Tablets Sales by Application in 2025
11.4.7 Cipla Limited Alfuzosin Hydrochloride Sustained Release Tablets Sales by Geographic Area in 2025
11.4.8 Cipla Limited Alfuzosin Hydrochloride Sustained Release Tablets SWOT Analysis
11.4.9 Cipla Limited Recent Developments
11.5 Sun Pharmaceutical Industries Limited
11.5.1 Sun Pharmaceutical Industries Limited Corporation Information
11.5.2 Sun Pharmaceutical Industries Limited Business Overview
11.5.3 Sun Pharmaceutical Industries Limited Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.5.4 Sun Pharmaceutical Industries Limited Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 Sun Pharmaceutical Industries Limited Alfuzosin Hydrochloride Sustained Release Tablets Sales by Product in 2025
11.5.6 Sun Pharmaceutical Industries Limited Alfuzosin Hydrochloride Sustained Release Tablets Sales by Application in 2025
11.5.7 Sun Pharmaceutical Industries Limited Alfuzosin Hydrochloride Sustained Release Tablets Sales by Geographic Area in 2025
11.5.8 Sun Pharmaceutical Industries Limited Alfuzosin Hydrochloride Sustained Release Tablets SWOT Analysis
11.5.9 Sun Pharmaceutical Industries Limited Recent Developments
11.6 Unichem Laboratories Limited
11.6.1 Unichem Laboratories Limited Corporation Information
11.6.2 Unichem Laboratories Limited Business Overview
11.6.3 Unichem Laboratories Limited Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.6.4 Unichem Laboratories Limited Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 Unichem Laboratories Limited Recent Developments
11.7 Aurobindo Pharma Limited
11.7.1 Aurobindo Pharma Limited Corporation Information
11.7.2 Aurobindo Pharma Limited Business Overview
11.7.3 Aurobindo Pharma Limited Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.7.4 Aurobindo Pharma Limited Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 Aurobindo Pharma Limited Recent Developments
11.8 Wockhardt Limited
11.8.1 Wockhardt Limited Corporation Information
11.8.2 Wockhardt Limited Business Overview
11.8.3 Wockhardt Limited Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.8.4 Wockhardt Limited Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 Wockhardt Limited Recent Developments
11.9 Rising Pharma Holdings, Inc.
11.9.1 Rising Pharma Holdings, Inc. Corporation Information
11.9.2 Rising Pharma Holdings, Inc. Business Overview
11.9.3 Rising Pharma Holdings, Inc. Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.9.4 Rising Pharma Holdings, Inc. Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 Rising Pharma Holdings, Inc. Recent Developments
11.10 Zentiva Group, a.s.
11.10.1 Zentiva Group, a.s. Corporation Information
11.10.2 Zentiva Group, a.s. Business Overview
11.10.3 Zentiva Group, a.s. Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.10.4 Zentiva Group, a.s. Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 Zentiva Group, a.s. Recent Developments
11.11 Taj Pharmaceuticals Limited
11.11.1 Taj Pharmaceuticals Limited Corporation Information
11.11.2 Taj Pharmaceuticals Limited Business Overview
11.11.3 Taj Pharmaceuticals Limited Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.11.4 Taj Pharmaceuticals Limited Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 Taj Pharmaceuticals Limited Recent Developments
11.12 Exelan Pharmaceuticals, Inc.
11.12.1 Exelan Pharmaceuticals, Inc. Corporation Information
11.12.2 Exelan Pharmaceuticals, Inc. Business Overview
11.12.3 Exelan Pharmaceuticals, Inc. Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.12.4 Exelan Pharmaceuticals, Inc. Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 Exelan Pharmaceuticals, Inc. Recent Developments
11.13 Lunan Better Pharmaceutical Co., Ltd.
11.13.1 Lunan Better Pharmaceutical Co., Ltd. Corporation Information
11.13.2 Lunan Better Pharmaceutical Co., Ltd. Business Overview
11.13.3 Lunan Better Pharmaceutical Co., Ltd. Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.13.4 Lunan Better Pharmaceutical Co., Ltd. Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 Lunan Better Pharmaceutical Co., Ltd. Recent Developments
11.14 Anxo Pharmaceutical Co., Ltd.
11.14.1 Anxo Pharmaceutical Co., Ltd. Corporation Information
11.14.2 Anxo Pharmaceutical Co., Ltd. Business Overview
11.14.3 Anxo Pharmaceutical Co., Ltd. Alfuzosin Hydrochloride Sustained Release Tablets Product Models, Descriptions and Specifications
11.14.4 Anxo Pharmaceutical Co., Ltd. Alfuzosin Hydrochloride Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 Anxo Pharmaceutical Co., Ltd. Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Alfuzosin Hydrochloride Sustained Release Tablets Industry Chain
12.2 Alfuzosin Hydrochloride Sustained Release Tablets Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Alfuzosin Hydrochloride Sustained Release Tablets Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Alfuzosin Hydrochloride Sustained Release Tablets Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Alfuzosin Hydrochloride Sustained Release Tablets Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Alfuzosin Hydrochloride Sustained Release Tablets Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Alfuzosin Hydrochloride Sustained Release Tablets Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Alfuzosin Hydrochloride Sustained Release Tablets Market Size Growth Rate by Prescription Duration, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Alfuzosin Hydrochloride Sustained Release Tablets Market Size Growth Rate by Brand Positioning, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Alfuzosin Hydrochloride Sustained Release Tablets Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Region (US$ Million), 2021-2026
Table 7. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Region (US$ Million), 2027-2032
Table 8. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (Million tablets)
Table 9. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales by Region (Million tablets), 2021-2026
Table 10. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales by Region (Million tablets), 2027-2032
Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 12. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales by Manufacturers (Million tablets), 2021-2026
Table 13. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Share by Manufacturers (2021-2026)
Table 14. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Manufacturers (US$ Million), 2021-2026
Table 15. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue-Based Market Share by Manufacturers (2021-2026)
Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Alfuzosin Hydrochloride Sustained Release Tablets Revenue, 2025
Table 18. Global Alfuzosin Hydrochloride Sustained Release Tablets Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 19. Global Alfuzosin Hydrochloride Sustained Release Tablets Average Selling Price (ASP) by Manufacturers (US$/tablet), 2021-2026
Table 20. Key Manufacturers Alfuzosin Hydrochloride Sustained Release Tablets Manufacturing Base and Headquarters
Table 21. Global Alfuzosin Hydrochloride Sustained Release Tablets Market Concentration Ratio (CR5)
Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 24. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume by Type (Million tablets), 2021-2026
Table 25. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume by Type (Million tablets), 2027-2032
Table 26. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Type (US$ Million), 2021-2026
Table 27. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Type (US$ Million), 2027-2032
Table 28. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume by Prescription Duration (Million tablets), 2021-2026
Table 29. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume by Prescription Duration (Million tablets), 2027-2032
Table 30. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Prescription Duration (US$ Million), 2021-2026
Table 31. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Prescription Duration (US$ Million), 2027-2032
Table 32. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume by Brand Positioning (Million tablets), 2021-2026
Table 33. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume by Brand Positioning (Million tablets), 2027-2032
Table 34. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Brand Positioning (US$ Million), 2021-2026
Table 35. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Brand Positioning (US$ Million), 2027-2032
Table 36. Technical Specifications by Key Product Type
Table 37. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales by Application (Million tablets), 2021-2026
Table 38. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales by Application (Million tablets), 2027-2032
Table 39. Alfuzosin Hydrochloride Sustained Release Tablets High-Growth Sectors Demand CAGR (2026-2032)
Table 40. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Application (US$ Million), 2021-2026
Table 41. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue by Application (US$ Million), 2027-2032
Table 42. Top Customers by Region
Table 43. Top Customers by Application
Table 44. North America Alfuzosin Hydrochloride Sustained Release Tablets Growth Accelerators and Market Barriers
Table 45. North America Alfuzosin Hydrochloride Sustained Release Tablets Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 46. North America Alfuzosin Hydrochloride Sustained Release Tablets Sales (Million tablets) by Country (2021 vs 2025 vs 2032)
Table 47. Europe Alfuzosin Hydrochloride Sustained Release Tablets Growth Accelerators and Market Barriers
Table 48. Europe Alfuzosin Hydrochloride Sustained Release Tablets Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Europe Alfuzosin Hydrochloride Sustained Release Tablets Sales (Million tablets) by Country (2021 vs 2025 vs 2032)
Table 50. Asia-Pacific Alfuzosin Hydrochloride Sustained Release Tablets Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 51. Asia-Pacific Alfuzosin Hydrochloride Sustained Release Tablets Sales (Million tablets) by Country (2021 vs 2025 vs 2032)
Table 52. Asia-Pacific Alfuzosin Hydrochloride Sustained Release Tablets Growth Accelerators and Market Barriers
Table 53. Southeast Asia Alfuzosin Hydrochloride Sustained Release Tablets Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 54. Central and South America Alfuzosin Hydrochloride Sustained Release Tablets Investment Opportunities and Key Challenges
Table 55. Central and South America Alfuzosin Hydrochloride Sustained Release Tablets Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 56. Middle East and Africa Alfuzosin Hydrochloride Sustained Release Tablets Investment Opportunities and Key Challenges
Table 57. Middle East and Africa Alfuzosin Hydrochloride Sustained Release Tablets Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 58. Sanofi Corporation Information
Table 59. Sanofi Description and Major Businesses
Table 60. Sanofi Product Models, Descriptions and Specifications
Table 61. Sanofi Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 62. Sanofi Sales Value Proportion by Product in 2025
Table 63. Sanofi Sales Value Proportion by Application in 2025
Table 64. Sanofi Sales Value Proportion by Geographic Area in 2025
Table 65. Sanofi Alfuzosin Hydrochloride Sustained Release Tablets SWOT Analysis
Table 66. Sanofi Recent Developments
Table 67. ADVANZ Pharma Corporation Information
Table 68. ADVANZ Pharma Description and Major Businesses
Table 69. ADVANZ Pharma Product Models, Descriptions and Specifications
Table 70. ADVANZ Pharma Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 71. ADVANZ Pharma Sales Value Proportion by Product in 2025
Table 72. ADVANZ Pharma Sales Value Proportion by Application in 2025
Table 73. ADVANZ Pharma Sales Value Proportion by Geographic Area in 2025
Table 74. ADVANZ Pharma Alfuzosin Hydrochloride Sustained Release Tablets SWOT Analysis
Table 75. ADVANZ Pharma Recent Developments
Table 76. Apotex Inc. Corporation Information
Table 77. Apotex Inc. Description and Major Businesses
Table 78. Apotex Inc. Product Models, Descriptions and Specifications
Table 79. Apotex Inc. Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 80. Apotex Inc. Sales Value Proportion by Product in 2025
Table 81. Apotex Inc. Sales Value Proportion by Application in 2025
Table 82. Apotex Inc. Sales Value Proportion by Geographic Area in 2025
Table 83. Apotex Inc. Alfuzosin Hydrochloride Sustained Release Tablets SWOT Analysis
Table 84. Apotex Inc. Recent Developments
Table 85. Cipla Limited Corporation Information
Table 86. Cipla Limited Description and Major Businesses
Table 87. Cipla Limited Product Models, Descriptions and Specifications
Table 88. Cipla Limited Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 89. Cipla Limited Sales Value Proportion by Product in 2025
Table 90. Cipla Limited Sales Value Proportion by Application in 2025
Table 91. Cipla Limited Sales Value Proportion by Geographic Area in 2025
Table 92. Cipla Limited Alfuzosin Hydrochloride Sustained Release Tablets SWOT Analysis
Table 93. Cipla Limited Recent Developments
Table 94. Sun Pharmaceutical Industries Limited Corporation Information
Table 95. Sun Pharmaceutical Industries Limited Description and Major Businesses
Table 96. Sun Pharmaceutical Industries Limited Product Models, Descriptions and Specifications
Table 97. Sun Pharmaceutical Industries Limited Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 98. Sun Pharmaceutical Industries Limited Sales Value Proportion by Product in 2025
Table 99. Sun Pharmaceutical Industries Limited Sales Value Proportion by Application in 2025
Table 100. Sun Pharmaceutical Industries Limited Sales Value Proportion by Geographic Area in 2025
Table 101. Sun Pharmaceutical Industries Limited Alfuzosin Hydrochloride Sustained Release Tablets SWOT Analysis
Table 102. Sun Pharmaceutical Industries Limited Recent Developments
Table 103. Unichem Laboratories Limited Corporation Information
Table 104. Unichem Laboratories Limited Description and Major Businesses
Table 105. Unichem Laboratories Limited Product Models, Descriptions and Specifications
Table 106. Unichem Laboratories Limited Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 107. Unichem Laboratories Limited Recent Developments
Table 108. Aurobindo Pharma Limited Corporation Information
Table 109. Aurobindo Pharma Limited Description and Major Businesses
Table 110. Aurobindo Pharma Limited Product Models, Descriptions and Specifications
Table 111. Aurobindo Pharma Limited Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 112. Aurobindo Pharma Limited Recent Developments
Table 113. Wockhardt Limited Corporation Information
Table 114. Wockhardt Limited Description and Major Businesses
Table 115. Wockhardt Limited Product Models, Descriptions and Specifications
Table 116. Wockhardt Limited Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 117. Wockhardt Limited Recent Developments
Table 118. Rising Pharma Holdings, Inc. Corporation Information
Table 119. Rising Pharma Holdings, Inc. Description and Major Businesses
Table 120. Rising Pharma Holdings, Inc. Product Models, Descriptions and Specifications
Table 121. Rising Pharma Holdings, Inc. Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 122. Rising Pharma Holdings, Inc. Recent Developments
Table 123. Zentiva Group, a.s. Corporation Information
Table 124. Zentiva Group, a.s. Description and Major Businesses
Table 125. Zentiva Group, a.s. Product Models, Descriptions and Specifications
Table 126. Zentiva Group, a.s. Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 127. Zentiva Group, a.s. Recent Developments
Table 128. Taj Pharmaceuticals Limited Corporation Information
Table 129. Taj Pharmaceuticals Limited Description and Major Businesses
Table 130. Taj Pharmaceuticals Limited Product Models, Descriptions and Specifications
Table 131. Taj Pharmaceuticals Limited Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 132. Taj Pharmaceuticals Limited Recent Developments
Table 133. Exelan Pharmaceuticals, Inc. Corporation Information
Table 134. Exelan Pharmaceuticals, Inc. Description and Major Businesses
Table 135. Exelan Pharmaceuticals, Inc. Product Models, Descriptions and Specifications
Table 136. Exelan Pharmaceuticals, Inc. Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 137. Exelan Pharmaceuticals, Inc. Recent Developments
Table 138. Lunan Better Pharmaceutical Co., Ltd. Corporation Information
Table 139. Lunan Better Pharmaceutical Co., Ltd. Description and Major Businesses
Table 140. Lunan Better Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 141. Lunan Better Pharmaceutical Co., Ltd. Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 142. Lunan Better Pharmaceutical Co., Ltd. Recent Developments
Table 143. Anxo Pharmaceutical Co., Ltd. Corporation Information
Table 144. Anxo Pharmaceutical Co., Ltd. Description and Major Businesses
Table 145. Anxo Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 146. Anxo Pharmaceutical Co., Ltd. Sales (Million tablets), Revenue (US$ Million), Price (US$/tablet) and Gross Margin (2021-2026)
Table 147. Anxo Pharmaceutical Co., Ltd. Recent Developments
Table 148. Key Raw Materials Distribution
Table 149. Raw Materials Key Suppliers
Table 150. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 151. Milestones in Production Technology Evolution
Table 152. Distributors List
Table 153. Market Trends and Market Evolution
Table 154. Market Drivers and Opportunities
Table 155. Market Challenges, Risks, and Restraints
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources

List of Figures
Figure 1. Alfuzosin Hydrochloride Sustained Release Tablets Product Picture
Figure 2. Global Alfuzosin Hydrochloride Sustained Release Tablets Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. 2.5mg Product Picture
Figure 4. 5mg Product Picture
Figure 5. 10mg Product Picture
Figure 6. Global Alfuzosin Hydrochloride Sustained Release Tablets Market Size Growth Rate by Prescription Duration, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Up to 30 Days Product Picture
Figure 8. 31–90 Days Product Picture
Figure 9. Above 90 Days Product Picture
Figure 10. Global Alfuzosin Hydrochloride Sustained Release Tablets Market Size Growth Rate by Brand Positioning, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Originator Premium Brand Product Picture
Figure 12. Regional Branded Generic Product Picture
Figure 13. Standard Retail Generic Product Picture
Figure 14. Institutional Tender Generic Product Picture
Figure 15. Global Alfuzosin Hydrochloride Sustained Release Tablets Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 16. Hospital
Figure 17. Clinic
Figure 18. Other
Figure 19. Alfuzosin Hydrochloride Sustained Release Tablets Report Years Considered
Figure 20. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 21. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 22. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 23. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue-Based Market Share by Region (2021-2032)
Figure 24. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales (Million tablets), 2021-2032
Figure 25. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (Million tablets)
Figure 26. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Market Share by Region (2021-2032)
Figure 27. Top 5 and Top 10 Manufacturers Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume Market Share in 2025
Figure 28. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue-Based Market Share Ranking (2025)
Figure 29. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 30. 2.5mg Revenue-Based Market Share by Manufacturer in 2025
Figure 31. 5mg Revenue-Based Market Share by Manufacturer in 2025
Figure 32. 10mg Revenue-Based Market Share by Manufacturer in 2025
Figure 33. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume-Based Market Share by Type (2021-2032)
Figure 34. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue-Based Market Share by Type (2021-2032)
Figure 35. Global Alfuzosin Hydrochloride Sustained Release Tablets ASP by Type (US$/tablet), 2021-2032
Figure 36. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume-Based Market Share by Prescription Duration (2021-2032)
Figure 37. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue-Based Market Share by Prescription Duration (2021-2032)
Figure 38. Global Alfuzosin Hydrochloride Sustained Release Tablets ASP by Prescription Duration (US$/tablet), 2021-2032
Figure 39. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume-Based Market Share by Brand Positioning (2021-2032)
Figure 40. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue-Based Market Share by Brand Positioning (2021-2032)
Figure 41. Global Alfuzosin Hydrochloride Sustained Release Tablets ASP by Brand Positioning (US$/tablet), 2021-2032
Figure 42. Global Alfuzosin Hydrochloride Sustained Release Tablets Sales Market Share by Application (2021-2032)
Figure 43. Global Alfuzosin Hydrochloride Sustained Release Tablets Revenue-Based Market Share by Application (2021-2032)
Figure 44. Global Alfuzosin Hydrochloride Sustained Release Tablets ASP by Application (US$/tablet), 2021-2032
Figure 45. North America Alfuzosin Hydrochloride Sustained Release Tablets Sales YoY (Million tablets), 2021-2032
Figure 46. North America Alfuzosin Hydrochloride Sustained Release Tablets Revenue YoY (US$ Million), 2021-2032
Figure 47. North America Top 5 Manufacturers Alfuzosin Hydrochloride Sustained Release Tablets Sales Revenue (US$ Million) in 2025
Figure 48. North America Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume (Million tablets) by Application (2021-2032)
Figure 49. North America Alfuzosin Hydrochloride Sustained Release Tablets Sales Revenue (US$ Million) by Application (2021-2032)
Figure 50. US Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 51. Canada Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 52. Mexico Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 53. Europe Alfuzosin Hydrochloride Sustained Release Tablets Sales YoY (Million tablets), 2021-2032
Figure 54. Europe Alfuzosin Hydrochloride Sustained Release Tablets Revenue YoY (US$ Million), 2021-2032
Figure 55. Europe Top 5 Manufacturers Alfuzosin Hydrochloride Sustained Release Tablets Sales Revenue (US$ Million) in 2025
Figure 56. Europe Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume (Million tablets) by Application (2021-2032)
Figure 57. Europe Alfuzosin Hydrochloride Sustained Release Tablets Sales Revenue (US$ Million) by Application (2021-2032)
Figure 58. Germany Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 59. France Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 60. U.K. Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 61. Italy Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 62. Russia Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 63. Asia-Pacific Alfuzosin Hydrochloride Sustained Release Tablets Sales YoY (Million tablets), 2021-2032
Figure 64. Asia-Pacific Alfuzosin Hydrochloride Sustained Release Tablets Revenue YoY (US$ Million), 2021-2032
Figure 65. Asia-Pacific Top 8 Manufacturers Alfuzosin Hydrochloride Sustained Release Tablets Sales Revenue (US$ Million) in 2025
Figure 66. Asia-Pacific Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume (Million tablets) by Application (2021-2032)
Figure 67. Asia-Pacific Alfuzosin Hydrochloride Sustained Release Tablets Sales Revenue (US$ Million) by Application (2021-2032)
Figure 68. Indonesia Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 69. Japan Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 70. South Korea Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 71. China Taiwan Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 72. India Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 73. Central and South America Alfuzosin Hydrochloride Sustained Release Tablets Sales YoY (Million tablets), 2021-2032
Figure 74. Central and South America Alfuzosin Hydrochloride Sustained Release Tablets Revenue YoY (US$ Million), 2021-2032
Figure 75. Central and South America Top 5 Manufacturers Alfuzosin Hydrochloride Sustained Release Tablets Sales Revenue (US$ Million) in 2025
Figure 76. Central and South America Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume (Million tablets) by Application (2021-2032)
Figure 77. Central and South America Alfuzosin Hydrochloride Sustained Release Tablets Sales Revenue (US$ Million) by Application (2021-2032)
Figure 78. Brazil Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 79. Argentina Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 80. Middle East, and Africa Alfuzosin Hydrochloride Sustained Release Tablets Sales YoY (Million tablets), 2021-2032
Figure 81. Middle East and Africa Alfuzosin Hydrochloride Sustained Release Tablets Revenue YoY (US$ Million), 2021-2032
Figure 82. Middle East and Africa Top 5 Manufacturers Alfuzosin Hydrochloride Sustained Release Tablets Sales Revenue (US$ Million) in 2025
Figure 83. Middle East and Africa Alfuzosin Hydrochloride Sustained Release Tablets Sales Volume (Million tablets) by Application (2021-2032)
Figure 84. Middle East and Africa Alfuzosin Hydrochloride Sustained Release Tablets Sales Revenue (US$ Million) by Application (2021-2032)
Figure 85. GCC Countries Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 86. Turkey Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 87. Egypt Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 88. South Africa Alfuzosin Hydrochloride Sustained Release Tablets Revenue (US$ Million), 2021-2032
Figure 89. Alfuzosin Hydrochloride Sustained Release Tablets Industry Chain Mapping
Figure 90. Regional Alfuzosin Hydrochloride Sustained Release Tablets Manufacturing Base Distribution (%)
Figure 91. Global Alfuzosin Hydrochloride Sustained Release Tablets Production Market Share by Region (2021-2032)
Figure 92. Alfuzosin Hydrochloride Sustained Release Tablets Production Process
Figure 93. Regional Alfuzosin Hydrochloride Sustained Release Tablets Production Cost Structure
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Bottom-up and Top-down Approaches for This Report
Figure 96. Data Triangulation
Figure 97. Key Executives Interviewed